Anti-EGFR-Based Therapy in Recurrent or Metastatic HNSCC – What Difference Does it Make?

References

• Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–1127. doi:10.1056/NEJMoa0802656.
   PubMed Web of Science ®Google Scholar
• Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2010;21(10):1967–1973. doi:10.1093/annonc/mdq077.
   PubMed Web of Science ®Google Scholar
• Argiris A, Harrington KJ, Tahara M, Schulten J, Chomette P, Ferreira Castro A, Licitra L. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Front Oncol. 2017;7:48–50. doi:10.3389/fonc.2017.00072.
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a andomized, open-label, phase 3 study. The Lancet. 2019;394(10212):1915–1928. doi:10.1016/S0140-6736(19)32591-7.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report Keytruda EMA/CHMP/591139/2019/corr. 2019.
   Google Scholar
• Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, andomized, phase 2 trial. The Lancet Oncology. 2021;22(4):463–475. doi:10.1016/S1470-2045(20)30755-5.
   PubMed Web of Science ®Google Scholar
• Guigay J, Fayette J, Mesia R, Saada-Bouzid E, Lafond C, Geoffrois L, GORTEC — AIO Studien gGmbH — TTCC — Unicancer H&N, et al. TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). JCO. 2020;38(15_suppl):6507–6507. doi:10.1200/JCO.2020.38.15_suppl.6507.
   Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–2177. doi:10.1200/JCO.2006.06.7447.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5578–5587. doi:10.1200/JCO.2005.07.120.
   PubMed Web of Science ®Google Scholar
• Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5568–5577. doi:10.1200/JCO.2005.07.119.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Toyoma S, Kawasaki Y, Koizumi K, Iikawa N, Shiina K, et al. Clinical outcomes of cetuximab and paclitaxel after progression on immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma. Medicina. 2021;57(11):1151. doi:10.3390/medicina57111151.
   PubMedGoogle Scholar
• Fasano M, Della Corte CM, Viscardi G, Di Liello R, Paragliola F, Sparano F, et al. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. Ther Adv Med Oncol. 2021;13:1758835920949418. doi:10.1177/1758835920949418.
   Web of Science ®Google Scholar
• Issa M, Klamer B, Karivedu V, Bhateja P, Laliotis GI, Dibs K, et al. Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma after progression on immune checkpoint inhibitors. JCO. 2021;39(15_suppl):6038–6038. doi:10.1200/JCO.2021.39.15_suppl.6038.
   Google Scholar
• Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021;22(6):883–892. doi:10.1016/S1470-2045(21)00136-4.
   PubMed Web of Science ®Google Scholar
• Szturz P, Vermorken JB. Revisiting EXTREME in the immuno-oncology era: how to improve its outcomes. Oncologist. 2021;26(11):899–901. doi:10.1002/onco.13966.
   PubMed Web of Science ®Google Scholar
• Szturz P, Vermorken JB. Translating KEYNOTE-048 into practice recommendations for head and neck cancer. Ann Transl Med. 2020;8(15):975–975. doi:10.21037/atm.2020.03.164.
   PubMed Web of Science ®Google Scholar
• Grünwald V, Chirovsky D, Cheung WY, Bertolini F, Ahn M-J, Yang M-H, GLANCE H&N STUDY Investigators, et al. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results of the GLANCE H&N study. Oral Oncol. 2020;102:104526. doi:10.1016/j.oraloncology.2019.104526.
   PubMed Web of Science ®Google Scholar